Advanced Accelerator Applications and NCI form clinical trial agreement

Advanced Accelerator Applications and NCI formed a clinical trial agreement: NCI plans to sponsor and conduct a study of Lutathera in patients with inoperable pheochromocytoma and paraganglioma.

Pheochromocytoma is a rare endocrine tumor originating in the adrenal glands. Paraganglioma is a tumor that is closely related to pheochromocytoma and originates from outside the adrenal glands. Both are considered orphan diseases.

Lutathera (lutetium Lu 177 dotatate) is a Lu-177-labeled somatostatin analogue peptide currently in development for the treatment of gastro entero pancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors in adults. Lutathera is a peptide receptor radionuclide therapy, which involves targeting carcinoid tumors with radiolabeled somatostatin analogue peptides. This compound has received orphan drug designation from the European Medicines Agency and the FDA.

DOWNLOAD THE PDF

Table of Contents

YOU MAY BE INTERESTED IN

Podcast

On Capitol Hill, NIH gets congressional support and RFK Jr. gets slammed

As NIH and NCI funding is negotiated in Congress, Paul W. Thurman felt compelled to crunch some numbers. He compared the U.S.’s cumulative funding for NCI to the funding slated for ICE—the latter of which vastly outweighs the former—and asked whether the funding priorities of the federal government are properly representing the nation’s mortality.

September 10, 2025

Vol.51 No.32

Bhattacharya fields NCAB’s questions about funding, political involvement in grant review, DEI, animal testing

On Sept. 4, Jay Bhattacharya did something NIH directors rarely do: he appeared before the National Cancer Advisory Board, speaking directly with the NCI advisory board about hot-button policy changes taking place under his leadership at NIH.

House committee’s FY26 spending bill increases NCI funding by $48M, NIH by $99M
House joins Senate in rejecting Trump’s proposed 40% NIH cuts

The House is on track to join the Senate in rejecting the Trump administration’s budget proposal that would cut NIH by $18 billion.

September 05, 2025

Vol.51 No.32

By Jacquelyn Cobb and Paul Goldberg

NCI Director's Report

Lowy: Forward-funding policy forced NCI to drastically reduce RPG awards funded for FY25, 10% of NCI staff has been lost

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January.

With CDC in free fall, RFK Jr. faces bipartisan rebuke at Senate hearing
Kennedy calls CDC “the most corrupt agency at HHS and maybe the government.”

A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.

September 05, 2025

Vol.51 No.32

By Claire Marie Porter

Guest Editorial

Curing cancer or curbing immigration: A question of national morality and priority

In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding.

September 05, 2025

Vol.51 No.32

By Paul W. Thurman

Advanced Accelerator Applications and NCI form clinical trial agreement

YOU MAY BE INTERESTED IN

On Capitol Hill, NIH gets congressional support and RFK Jr. gets slammed

Bhattacharya fields NCAB’s questions about funding, political involvement in grant review, DEI, animal testing

House committee’s FY26 spending bill increases NCI funding by $48M, NIH by $99M
House joins Senate in rejecting Trump’s proposed 40% NIH cuts

Lowy: Forward-funding policy forced NCI to drastically reduce RPG awards funded for FY25, 10% of NCI staff has been lost

With CDC in free fall, RFK Jr. faces bipartisan rebuke at Senate hearing
Kennedy calls CDC “the most corrupt agency at HHS and maybe the government.”

Curing cancer or curbing immigration: A question of national morality and priority

Renew today!

Subscriber content

Never miss an issue!

Login

Advanced Accelerator Applications and NCI form clinical trial agreement

YOU MAY BE INTERESTED IN

On Capitol Hill, NIH gets congressional support and RFK Jr. gets slammed

Bhattacharya fields NCAB’s questions about funding, political involvement in grant review, DEI, animal testing

House committee’s FY26 spending bill increases NCI funding by $48M, NIH by $99MHouse joins Senate in rejecting Trump’s proposed 40% NIH cuts

Lowy: Forward-funding policy forced NCI to drastically reduce RPG awards funded for FY25, 10% of NCI staff has been lost

With CDC in free fall, RFK Jr. faces bipartisan rebuke at Senate hearingKennedy calls CDC “the most corrupt agency at HHS and maybe the government.”

Curing cancer or curbing immigration: A question of national morality and priority

Never miss an issue!

Login

House committee’s FY26 spending bill increases NCI funding by $48M, NIH by $99M
House joins Senate in rejecting Trump’s proposed 40% NIH cuts

With CDC in free fall, RFK Jr. faces bipartisan rebuke at Senate hearing
Kennedy calls CDC “the most corrupt agency at HHS and maybe the government.”